Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

ADVAX

Alternative Names: ADVAX
Latest Update: 2025-02-16
Latest Update Note: Clinical Trial Update

Product Description

a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes (Sourced from: https://www.iavi.org/news-resources/iavi-partner-scientific-publications/phase-1-safety-and-immunogenicity-evaluation-of-advax-a-multigenic-dna-based-clade-c-b-hiv-1-candidate-vaccine)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vaxine Pty
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ADVAX

Countries in Clinic: Australia

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: COVID-19

Phase 1: Alzheimer Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ACTRN12624000737538

P1

Recruiting

Alzheimer Disease

2025-02-14

SpikoGen

P3

Active, not recruiting

COVID-19

2023-12-31

Recent News Events

Date

Type

Title

02/15/2024

PubMed

 Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.

01/26/2024

PubMed

 Lung IL-17A-Producing CD4+ T Cells Correlate with Protection after Intrapulmonary Vaccination with Differentially Adjuvanted Tuberculosis Vaccines.

12/29/2023

PubMed

 A Multi-Season Randomised Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants with Chronic Disease or Older Age.

06/13/2023

News Article

 Moat Biotechnology Raises $6.5M in First Close for Intranasal/Inhaled Covid-19 Vaccine

03/29/2022

News Article

 Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions